TGTX 12.81 Tg Therapeutics $TGTX Hit a 52 week hig
Post# of 118
Posted On: 11/12/2014 2:54:11 PM
TGTX 12.81 Tg Therapeutics $TGTX Hit a 52 week high of 12.88 Closing the day 09:42 at 12.81 -0.10 -0.77% With a day low of 12.64 and a total volume of 28,808.
TGTX Recent Posts: http://investorshangout.com/TG-Therapeutics-Inc-TGTX-64219/
TGTX Tg Therapeutics Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 84.01 (+3.14), OREX: 5.83 (+0.79), PCMI: 8.90 (unch), CYAN: 6.00 (-0.06), ACHN: 14.46 (+1.98), TGTX: 13.83 (+0.92), AGIO: 87.18 (+5.27), LIOX: 5.41 (-0.02), SAJA: 5.90 (-0.35), PLNR: 6.95 (+0.14)
TG Therapeutics' (TGTX) CEO Michael Weiss on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 2:03PM CST
TGTX: 13.83 (+0.92)
TG Therapeutics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:10AM CST
TGTX: 13.77 (+0.86)
TG Therapeutics posts 3Q loss
Automated Insights - Tue Nov 11, 4:11AM CST
NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Tuesday reported a loss of $17.5 million, or 51 cents per share, in its third quarter.
TGTX: 13.77 (+0.86)
TG Therapeutics misses by $0.19
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:12PM CST
TGTX: 13.77 (+0.86)
TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Mon Nov 10, 3:20PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for cancer and autoimmune diseases, today announced its results for the third quarter ended September 30, 2014 and recent company developments.
TGTX: 13.75 (+0.84)
TG Therapeutics reports November 11
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:10PM CST
TGTX: 13.75 (+0.84)
TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Fri Nov 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that a conference call will be held on Tuesday, November 11, 2014 at 8:30am ET to discuss results for the third quarter of 2014 and provide a business outlook for the remainder of the year. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 13.83 (+0.92)
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:45AM CST
Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation
TGTX: 13.83 (+0.92)
Strong On High Relative Volume: TG Therapeutics (TGTX)
at The Street - Mon Oct 27, 9:00AM CDT
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate
TGTX: 13.83 (+0.92)
Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 12:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) earned a $550,000 milestone payment from partner Merck (MRK) on the EU approval of Noxafil (posaconazole) for infusion.
MRK: 59.24 (-0.13), TGTX: 13.83 (+0.92), LGND: 57.41 (+0.51), AMGN: 162.05 (-0.37)
TG Therapeutics reports exercise of its option to license the global rights to TGR-1202
M2 - Wed Sep 24, 6:17AM CDT
Biopharmaceutical company TG Therapeutics (NasdaqCM :TGTX) said on Tuesday that it has exercised its option to license the global rights to TGR-1202 from Rhizen Pharmaceuticals.
TGTX: 13.83 (+0.92)
Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG Therapeutics exercised its option for early conversion to a licensing agreement from a 50:50 joint venture partnership.
TGTX: 13.82 (+0.91)
TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
GlobeNewswire - Tue Sep 23, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A ("Rhizen"
. The Company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the Company's license option.
TGTX: 13.82 (+0.91)
TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:46AM CDT
TG Therapeutics (TGTX) was a big mover last session, with shares rising over 16% on the day.
ICUI: 84.01 (+3.14), ABAX: 53.79 (+0.29), TGTX: 13.82 (+0.91), EGRX: 12.97 (-0.56)
TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval
TGTX: 13.82 (+0.91)
UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 3:28PM CDT
In a release issued earlier today by TG Therapeutics, Inc. (Nasdaq:TGTX), please note the company's scheduled presentation time has changed to 1:15 PM ET, from 1:40 PM ET previously. The updated release follows:
TGTX: 13.82 (+0.91)
TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:12AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 16 Annual Rodman & Renshaw Global Investment Conference being held at the New York Palace Hotel. Mr. Weiss' presentation is scheduled to take place on Tuesday, September 9, 2014 at 1:40 PM ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section of the Company's website at www.tgtherapeutics.com.
TGTX: 13.78 (+0.87)
TGTX Recent Posts: http://investorshangout.com/TG-Therapeutics-Inc-TGTX-64219/
TGTX Tg Therapeutics Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 84.01 (+3.14), OREX: 5.83 (+0.79), PCMI: 8.90 (unch), CYAN: 6.00 (-0.06), ACHN: 14.46 (+1.98), TGTX: 13.83 (+0.92), AGIO: 87.18 (+5.27), LIOX: 5.41 (-0.02), SAJA: 5.90 (-0.35), PLNR: 6.95 (+0.14)
TG Therapeutics' (TGTX) CEO Michael Weiss on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 2:03PM CST
TGTX: 13.83 (+0.92)
TG Therapeutics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:10AM CST
TGTX: 13.77 (+0.86)
TG Therapeutics posts 3Q loss
Automated Insights - Tue Nov 11, 4:11AM CST
NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Tuesday reported a loss of $17.5 million, or 51 cents per share, in its third quarter.
TGTX: 13.77 (+0.86)
TG Therapeutics misses by $0.19
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:12PM CST
TGTX: 13.77 (+0.86)
TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Mon Nov 10, 3:20PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for cancer and autoimmune diseases, today announced its results for the third quarter ended September 30, 2014 and recent company developments.
TGTX: 13.75 (+0.84)
TG Therapeutics reports November 11
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:10PM CST
TGTX: 13.75 (+0.84)
TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Fri Nov 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that a conference call will be held on Tuesday, November 11, 2014 at 8:30am ET to discuss results for the third quarter of 2014 and provide a business outlook for the remainder of the year. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 13.83 (+0.92)
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:45AM CST
Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation
TGTX: 13.83 (+0.92)
Strong On High Relative Volume: TG Therapeutics (TGTX)
at The Street - Mon Oct 27, 9:00AM CDT
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate
TGTX: 13.83 (+0.92)
Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 12:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) earned a $550,000 milestone payment from partner Merck (MRK) on the EU approval of Noxafil (posaconazole) for infusion.
MRK: 59.24 (-0.13), TGTX: 13.83 (+0.92), LGND: 57.41 (+0.51), AMGN: 162.05 (-0.37)
TG Therapeutics reports exercise of its option to license the global rights to TGR-1202
M2 - Wed Sep 24, 6:17AM CDT
Biopharmaceutical company TG Therapeutics (NasdaqCM :TGTX) said on Tuesday that it has exercised its option to license the global rights to TGR-1202 from Rhizen Pharmaceuticals.
TGTX: 13.83 (+0.92)
Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG Therapeutics exercised its option for early conversion to a licensing agreement from a 50:50 joint venture partnership.
TGTX: 13.82 (+0.91)
TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
GlobeNewswire - Tue Sep 23, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A ("Rhizen"
. The Company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the Company's license option. TGTX: 13.82 (+0.91)
TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:46AM CDT
TG Therapeutics (TGTX) was a big mover last session, with shares rising over 16% on the day.
ICUI: 84.01 (+3.14), ABAX: 53.79 (+0.29), TGTX: 13.82 (+0.91), EGRX: 12.97 (-0.56)
TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval
TGTX: 13.82 (+0.91)
UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 3:28PM CDT
In a release issued earlier today by TG Therapeutics, Inc. (Nasdaq:TGTX), please note the company's scheduled presentation time has changed to 1:15 PM ET, from 1:40 PM ET previously. The updated release follows:
TGTX: 13.82 (+0.91)
TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:12AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 16 Annual Rodman & Renshaw Global Investment Conference being held at the New York Palace Hotel. Mr. Weiss' presentation is scheduled to take place on Tuesday, September 9, 2014 at 1:40 PM ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section of the Company's website at www.tgtherapeutics.com.
TGTX: 13.78 (+0.87)
(0)
(0)TG Therapeutics Inc. (TGTX) Stock Research Links
Scroll down for more posts ▼